Clinical Scorecard: The First NCI-Designated Comprehensive Cancer Center Using 3D Genomics Testing to Diagnose Lymphoma and Sarcoma—a True Game Changer

At a Glance

Key Highlights

• Introduction of 3D genomics testing for improved diagnosis of lymphoma and sarcoma
• Ability to identify structural changes in DNA that drive cancer behavior
• Reduction in diagnostic uncertainty leading to quicker treatment decisions
• Utilization of existing slides for testing, enhancing accessibility
• Integration with standard genomic testing for proactive treatment planning

Guideline-Based Recommendations

Diagnosis

• Use 3D genomics testing to differentiate between closely related subtypes of lymphoma and sarcoma
• Reclassify cancers previously labeled 'not otherwise specified' for clearer treatment direction

Management

• Select therapies aligned with the specific tumor biology identified through 3D testing
• Implement targeted treatment plans sooner based on improved diagnostic clarity

Monitoring & Follow-up

• Regularly assess genomic changes to inform ongoing treatment strategies

Risks

• Potential for relapse into unresponsive states despite advances in treatment

Patient & Prescribing Data

Patients diagnosed with lymphoma and sarcoma requiring precise genomic insights

3D genomics testing aids in identifying gene fusions and rearrangements critical for treatment decisions

Clinical Best Practices

• Incorporate 3D genomics testing into routine diagnostic workflows
• Utilize existing biopsy slides for testing to minimize patient discomfort
• Engage in interdisciplinary collaboration to enhance treatment planning

References

• Fox Chase Cancer Center
• Arima Genomics, Inc.